Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frauke Stascheit

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Der Nervenarzt|August 23, 2022
[Public health situation of CIDP patients in nine German centers-neuritis network Germany]Anna Lena Fisse, Jeremias Motte, Thomas Grüter, et al.
Journal of Neurology|September 27, 2022
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravisFrauke Stascheit, Ulrike Grittner, Sarah Hoffmann, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2022
Eculizumab versus rituximab in generalised myasthenia gravisChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.
European Journal of Neurology|April 15, 2026
Complement Inhibition Therapy in Myasthenic Crisis-A Multicentre Retrospective Analysis of 17 Cases From GermanyLea Gerischer, Maike Stein, Alice Schneider, et al.
Neurological Research and Practice|May 13, 2026
Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocolFelix Kohle, Franz Felix Konen, Ulrike Grittner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2025
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravisNiklas Huntemann, Lea Gerischer, Meret Herdick, et al.
Journal of Neurology|February 27, 2026
Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort studyMenekse Oeztuerk, Niklas Huntemann, Lea Gerischer, et al.
Acta Neuropathologica|June 18, 2024
Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravisChristina B Schroeter, Christopher Nelke, Frauke Stascheit, et al.
Journal of Neurology|July 11, 2024
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohortPaula Quint, Christina B Schroeter, Felix Kohle, et al.
Brain : a Journal of Neurology|June 7, 2026
Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron diseaseFriederike A Arlt, Ramona Miske, Luise Appeltshauser, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Der Nervenarzt|August 23, 2022
[Public health situation of CIDP patients in nine German centers-neuritis network Germany]Anna Lena Fisse, Jeremias Motte, Thomas Grüter, et al.
Journal of Neurology|September 27, 2022
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravisFrauke Stascheit, Ulrike Grittner, Sarah Hoffmann, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2022
Eculizumab versus rituximab in generalised myasthenia gravisChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.
European Journal of Neurology|April 15, 2026
Complement Inhibition Therapy in Myasthenic Crisis-A Multicentre Retrospective Analysis of 17 Cases From GermanyLea Gerischer, Maike Stein, Alice Schneider, et al.
Neurological Research and Practice|May 13, 2026
Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocolFelix Kohle, Franz Felix Konen, Ulrike Grittner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2025
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravisNiklas Huntemann, Lea Gerischer, Meret Herdick, et al.
Journal of Neurology|February 27, 2026
Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort studyMenekse Oeztuerk, Niklas Huntemann, Lea Gerischer, et al.
Acta Neuropathologica|June 18, 2024
Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravisChristina B Schroeter, Christopher Nelke, Frauke Stascheit, et al.
Journal of Neurology|July 11, 2024
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohortPaula Quint, Christina B Schroeter, Felix Kohle, et al.
Brain : a Journal of Neurology|June 7, 2026
Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron diseaseFriederike A Arlt, Ramona Miske, Luise Appeltshauser, et al.
Pageof 6